Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL416493 | 0.81 | DCUN1D1 (0.54) | NCOA1LMNAGAAKMT2A | |
| SCHEMBL16481674 | 0.77 | PDE5A (0.52) | — | |
| SCHEMBL419538 | 0.77 | DHODH (0.45) | MAPK13GCGRMAPK12MAPK11MAPK14 | |
| SCHEMBL16067353 | 0.76 | POLB (0.50) | — | |
| SCHEMBL16481640 | 0.75 | PDE5A (0.54) | LMNAKMT2A | |
| SCHEMBL417398 | 0.73 | DHODH (0.47) | MAPK13GCGRMAPK12MAPK11MAPK14 | |
| SCHEMBL2203391 | 0.72 | TSHR (0.58) | BRD4PTGS2NCOA1NCOA3LMNA | |
| SCHEMBL1528147 | 0.72 | IDO1 (0.53) | — | |
| SCHEMBL6406032 | 0.70 | NCOA1 (0.55) | BRD4PTGS2NCOA1NCOA3LMNA | |
| SCHEMBL28856671 | 0.70 | BRD4 (0.52) | BRD4PTGS2NCOA1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022083-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2012-01-26 | — | — | US | claimed |
| US-20090291967-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2009-11-26 | — | — | US | claimed |
| US-20120022083-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20120022083-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20120022083-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20090291967-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2009-11-26 | — | — | US | disclosed |
| US-20090291967-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2009-11-26 | — | — | US | disclosed |
| US-20090291967-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291967-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | CDH1, EPCAM, ICAM1 | BRD4 1964/4885MAPK13 2187/4885GCGR 2394/4885 |
| US-20120022083-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | CDH1, EPCAM, ICAM1 | BRD4 1964/4885MAPK13 2187/4885GCGR 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.